Recent publications, longitudinal cohorts, and clinical practice updates from The New England Journal of Medicine, The Lancet, JAMA, BMJ, and Nature Medicine. Every study summary reports the trial design, participant sample size (N), primary outcome highlight, and direct link to the formal NCBI PubMed or federal record.
The Plain-English Receipt: Only 1.2% of prediabetic adults on Tirzepatide progressed to Type 2 diabetes over 3.4 years vs. 19.3% on placebo (Absolute Risk Reduction = 18.1% • Number Needed to Treat = 6).
New England Journal of Medicine, Volume 395, Issue 17 , Page 1728-1743, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1765-1767, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1758-1759, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1763-1765, October 29, 2026.
Nature Medicine, Published online: 28 October 2026; doi:10.1038/s41591-026-04748-1 Editorial Expression of Concern: MicroRNA-133 controls cardiac hypertrophy
New England Journal of Medicine, Volume 395, Issue 17 , Page 1768-1771, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1767-1768, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1760-1763, October 29, 2026.
This Medical News article discusses a randomized clinical trial that compared the metabolic effects of 10% weight loss with a Mediterranean diet, a very low-fat, plant-forward diet, and a very low-carbohydrate ketogenic diet.
This Medical News article discusses how children are using artificial intelligence (AI) chatbots for emotional support and the challenges of developing evidence and mental health safeguards quickly enough to keep pace with the technology.
In the absence of updated federal guidance for the 2026 to 2027 respiratory virus season, US medical societies have published their own vaccine recommendations based on evidence reviews from the Vaccine Integrity Project, an initiative of the Center for Infect
The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology found.
This randomized clinical trial examines whether adopting a permissive mean arterial blood pressure target improves outcomes in critically ill children with hypotension.
Few explicit policies exist to address cognitive decline among aging physicians, a study published in JAMA Health Forum found.
The US Centers for Disease Control and Prevention (CDC) issued a health advisory in response to reports of increased human exposure to rabid or possibly rabid animals.
“Do I need to treat this blood pressure?” is one of the most common questions to pass through the minds of acute care pediatricians during a typical day in the hospital. Blood pressure generally increases with somatic growth, reflecting developmental changes i
Nature Medicine, Published online: 27 October 2026; doi:10.1038/s41591-026-04751-6 Author Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
The American Heart Association (AHA) announced that its PREVENT equations are now integrated into Epic’s electronic health record platform.
Listen to the JAMA Editor’s Summary for an overview and discussion of the important articles appearing in JAMA.
The incidence of autism spectrum disorder in South Korea remained stable across cohorts born from 1998 to 2010, according to a study published in JAMA Pediatrics.
New England Journal of Medicine, Volume 395, Issue 18 , Page 1830-1840, November 5, 2026.
Heavy menstrual bleeding is a challenging condition that, when refractory to conventional treatment, frequently culminates in hysterectomy. Endometrial ablation offers an effective, uterus-sparing alternative for women who do not desire future childbearing, wi
For decades, the standard of care for patients with resected stage II and III colon cancer has centred on surgery with consideration of postoperative adjuvant systemic therapy to reduce risk of recurrence. Mismatch repair deficiency is seen in 10–15% of non-me
New England Journal of Medicine, Volume 395, Issue 17 , Page 1677-1690, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1717-1727, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 18 , Page 1781-1793, November 5, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1703-1716, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 17 , Page 1691-1702, October 29, 2026.
New England Journal of Medicine, Volume 395, Issue 18 , Page 1794-1804, November 5, 2026.
New England Journal of Medicine, Volume 395, Issue 18 , Page 1818-1829, November 5, 2026.
Traditional health headlines often exaggerate findings by reporting only Relative Risk Reduction—for example, claiming a drug cuts risk by 50% when the event rate dropped from 2% to 1% (an Absolute Risk Reduction of just 1.0 percentage point, meaning 100 patients must take the drug for 1 person to benefit, or NNT = 100). On dotMD, every flagship study breakdown reports both Relative Risk and Absolute Risk alongside the exact sample size (N) and trial duration.
Every study on dotMD displays its exact Study Design Tier at the top of the card (Phase 3 Randomized Trial, Randomized Controlled Trial, Meta-Analysis & Systematic Review, Multi-Trial Clinical Evidence Synthesis, Journal Watch Cohort, or FDA Safety Alert) along with the human participant count (N). Preclinical mouse or cell-culture data is never presented as human clinical proof.
Arbitrary 0-to-100 rigor scores obscure what actually makes a study trustworthy. Instead of synthetic scores, dotMD surfaces the verifiable primary evidence signals: exact NCBI PubMed IDs (PMID), ClinicalTrials.gov registration numbers (NCT), double-blind vs. crossover design, sample size (N), p-values / Hazard Ratios, and study limitations.
Medical research is only useful if you can act on it safely with your clinician. Every flagship research synthesis links directly to the parent Condition diagnostic cutoff guide, the Medication FDA DailyMed & CMS NADAC wholesale price ledger, the Supplement elemental weight decoder, and our High-CPT-Volume Specialist Directory.
